Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504935 | 1.00 | EGFR (0.78) | EGFRERBB2 | |
| SCHEMBL1417841 | 0.88 | EGFR (0.60) | EGFRERBB2 | |
| SCHEMBL6502203 | 0.88 | EGFR (0.60) | EGFRERBB2 | |
| SCHEMBL1418142 | 0.88 | EGFR (0.79) | EGFRERBB2 | |
| SCHEMBL1418144 | 0.88 | EGFR (0.79) | EGFRERBB2 | |
| SCHEMBL4187489 | 0.88 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL6505388 | 0.84 | EGFR (0.58) | EGFRERBB2 | |
| SCHEMBL1417833 | 0.84 | EGFR (0.67) | EGFRERBB2 | |
| SCHEMBL6505387 | 0.84 | EGFR (0.58) | EGFRERBB2 | |
| SCHEMBL1417831 | 0.84 | EGFR (0.67) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972288-B1 | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-12-06 | — | — | US | disclosed |
| EP-1157011-A1 | 4-AMINO- QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | Boehringer Ingelheim Pharma KG (DE) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000051991-A1 | 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-08 | — | — | WO | disclosed |